A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms
Randomized trial reports higher overall survival with CLAG-M versus CPX-351 in adults with acute myeloid leukemia, suggesting benefits of intensive therapy.
Key Points
CLAG-M led to numerically higher remission rates in acute myeloid leukemia compared to CPX-351.
Overall survival at three months showed 70% with CLAG-M versus 60% with CPX-351.
Observational analysis across 60 participants demonstrated varying response rates and toxicity profiles between regimens.
Results indicate intensive therapy may warrant further investigation in medically less-fit patients with acute myeloid leukemia.